| アブストラクト | BACKGROUND: Cancer cachexia is a multifactorial syndrome leading to progressive functional impairment. How cachexia affects the treatment course of chemotherapy in patients with pancreatic cancer has not been well understood. METHODS: This is an exploratory, retrospective, observational cohort study using the Japanese medical claims database from Medical Data Vision Co., Ltd. The study population included patients diagnosed with pancreatic cancer in whom first-line FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) was initiated between October 1, 2018, and September 30, 2020. In this study, we defined patients with cancer cachexia as those who had a weight loss of >/= 5% in the preceding 6 months. The primary outcome was time-to-treatment failure (TTF). The observation period was six months from the initiation of first-line FFX or GnP treatment. RESULTS: A total of 1897 patients (421 patients into the cachexia group; 1476 patients into the non-cachexia group) were analyzed in this study. The median TTF was 121 days (95% confidence interval [CI] 94-146) in the cachexia group and 143 days (95% CI 134-152) in the non-cachexia group. The hazard ratio for TTF of the cachexia versus non-cachexia group was 1.136 (95% CI 0.979-1.319). The median number of doses was two doses fewer in the cachexia group than in the non-cachexia group for both FFX and GnP. CONCLUSION: Cancer cachexia was suggested to be associated with shorter TTF and a reduced number of doses in patients with pancreatic cancer who received first-line FFX or GnP treatment. Clinical Trial Registration clinicaltrials.jp: UMIN000045820. |
|---|
| 組織名 | Department of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku,;Yokohama, 241-8515, Japan. junjifuruse@yahoo.co.jp.;Medical Affairs, Ono Pharmaceutical Co., Ltd., 8-2, Kyutaromachi 1-Chome Chuo-Ku,;Osaka-Shi, 541-8564, Japan.;Digital Strategy & Planning, Ono Pharmaceutical Co., Ltd., 8-2, Kyutaromachi;1-Chome Chuo-Ku, Osaka-Shi, 541-8564, Japan. |
|---|
